The promise of N-acetylcysteine in neuropsychiatry - PubMed

Review

The promise of N-acetylcysteine in neuropsychiatry

Michael Berk et al. Trends Pharmacol Sci. 2013 Mar.

Abstract

N-Acetylcysteine (NAC) targets a diverse array of factors germane to the pathophysiology of multiple neuropsychiatric disorders including glutamatergic transmission, the antioxidant glutathione, neurotrophins, apoptosis, mitochondrial function, and inflammatory pathways. This review summarises the areas where the mechanisms of action of NAC overlap with known pathophysiological elements, and offers a précis of current literature regarding the use of NAC in disorders including cocaine, cannabis, and smoking addictions, Alzheimer's and Parkinson's diseases, autism, compulsive and grooming disorders, schizophrenia, depression, and bipolar disorder. There are positive trials of NAC in all these disorders, and although many of these require replication and are methodologically preliminary, this makes it one of the most promising drug candidates in neuropsychiatric disorders. The efficacy pattern of NAC interestingly shows little respect for the current diagnostic systems. Its benign tolerability profile, its action on multiple operative pathways, and the emergence of positive trial data make it an important target to investigate.

Similar articles

• N-acetylcysteine in the treatment of psychiatric disorders: current status and future prospects.

  Minarini A, Ferrari S, Galletti M, Giambalvo N, Perrone D, Rioli G, Galeazzi GM. Minarini A, et al. Expert Opin Drug Metab Toxicol. 2017 Mar;13(3):279-292. doi: 10.1080/17425255.2017.1251580. Epub 2016 Nov 2. Expert Opin Drug Metab Toxicol. 2017. PMID: 27766914 Review.

• Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review.

  Deepmala, Slattery J, Kumar N, Delhey L, Berk M, Dean O, Spielholz C, Frye R. Deepmala, et al. Neurosci Biobehav Rev. 2015 Aug;55:294-321. doi: 10.1016/j.neubiorev.2015.04.015. Epub 2015 May 6. Neurosci Biobehav Rev. 2015. PMID: 25957927 Review.

• N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action.

  Dean O, Giorlando F, Berk M. Dean O, et al. J Psychiatry Neurosci. 2011 Mar;36(2):78-86. doi: 10.1503/jpn.100057. J Psychiatry Neurosci. 2011. PMID: 21118657 Free PMC article. Review.

• Putative neuroprotective agents in neuropsychiatric disorders.

  Dodd S, Maes M, Anderson G, Dean OM, Moylan S, Berk M. Dodd S, et al. Prog Neuropsychopharmacol Biol Psychiatry. 2013 Apr 5;42:135-45. doi: 10.1016/j.pnpbp.2012.11.007. Epub 2012 Nov 23. Prog Neuropsychopharmacol Biol Psychiatry. 2013. PMID: 23178231 Review.

• Overview on the Effects of N-Acetylcysteine in Neurodegenerative Diseases.

  Tardiolo G, Bramanti P, Mazzon E. Tardiolo G, et al. Molecules. 2018 Dec 13;23(12):3305. doi: 10.3390/molecules23123305. Molecules. 2018. PMID: 30551603 Free PMC article. Review.

Cited by

• Early interventions in risk groups for schizophrenia: what are we waiting for?

  Sommer IE, Bearden CE, van Dellen E, Breetvelt EJ, Duijff SN, Maijer K, van Amelsvoort T, de Haan L, Gur RE, Arango C, Díaz-Caneja CM, Vinkers CH, Vorstman JA. Sommer IE, et al. NPJ Schizophr. 2016 Mar 9;2:16003. doi: 10.1038/npjschz.2016.3. eCollection 2016. NPJ Schizophr. 2016. PMID: 27336054 Free PMC article. Review.

• An investigation of the effects of N-acetylcysteine on radiotherapy-induced testicular injury in rats.

  Topcu A, Mercantepe F, Rakici S, Tumkaya L, Uydu HA, Mercantepe T. Topcu A, et al. Naunyn Schmiedebergs Arch Pharmacol. 2019 Feb;392(2):147-157. doi: 10.1007/s00210-018-1581-6. Epub 2018 Nov 13. Naunyn Schmiedebergs Arch Pharmacol. 2019. PMID: 30426142

• N-acetylcysteine targets 5 lipoxygenase-derived, toxic lipids and can synergize with prostaglandin E₂ to inhibit ferroptosis and improve outcomes following hemorrhagic stroke in mice.

  Karuppagounder SS, Alin L, Chen Y, Brand D, Bourassa MW, Dietrich K, Wilkinson CM, Nadeau CA, Kumar A, Perry S, Pinto JT, Darley-Usmar V, Sanchez S, Milne GL, Pratico D, Holman TR, Carmichael ST, Coppola G, Colbourne F, Ratan RR. Karuppagounder SS, et al. Ann Neurol. 2018 Dec;84(6):854-872. doi: 10.1002/ana.25356. Epub 2018 Nov 29. Ann Neurol. 2018. PMID: 30294906 Free PMC article.

• Selective Serotonin Reuptake Inhibitors and Nutraceutical Combination in Major Depression Disorder: A Case-Control Study.

  Ielmini M, Caselli I, Ceccon F, Diurni M, Poloni N, Callegari C. Ielmini M, et al. Psychopharmacol Bull. 2021 Nov 3;51(4):31-39. Psychopharmacol Bull. 2021. PMID: 34887597 Free PMC article.

• Advanced pharmacotherapy evidenced by pathogenesis of autism spectrum disorder.

  Lee YJ, Oh SH, Park C, Hong M, Lee AR, Yoo HJ, Shin CY, Cheon KA, Bahn GH. Lee YJ, et al. Clin Psychopharmacol Neurosci. 2014 Apr;12(1):19-30. doi: 10.9758/cpn.2014.12.1.19. Epub 2014 Apr 24. Clin Psychopharmacol Neurosci. 2014. PMID: 24851117 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • ClinicalKey
  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database
  • scite Smart Citations

• Medical

  • MedlinePlus Health Information